Q Zhao1, G Tian2, D Kong3, T Jiang4. 1. Department of Hepatobiliary Pancreatic Surgery, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China. 2. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China. 3. Department of Mathematics, Zhejiang University, Hangzhou, 310027, China. 4. Department of Ultrasound, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China. tiananjiang@126.com.
Abstract
OBJECTIVES: Our aim was to evaluate the efficacy of ultrasound-guided radiofrequency ablation (RFA) for localized recurrent thyroid cancers. METHODS: We did a systematic review and meta-analysis of the scientific literature by searching the PubMed, Embase, Web of Science,Scopus and the Cochrane Library up to November 26, 2015. We assessed the pooled standard mean difference (SMD) of nodule volume, largest diameter and serum thyroglobulin (Tg) level by comparing pre-RFA with post-RFA using fixed or random-effects model. The Newcastle-Ottawa Scale was used to evaluate the methodological quality of the included studies, risk of bias in the selective populations, comparability of groups and exposure. RESULTS: We finally identified nine articles including 189 patients (male: 54 and female: 135) with 255 tumor lesions, who underwent ultrasound (US)-guided RFA beyond the mean 6 months of follow-up. The results showed that tumor volume (SWD: 0.77, 95 % CI: 0.57-0.97, I (2) = 25.9 %, p = 0.231), largest diameter (SWD: 1.56, 95 % CI: 0.94-2.17, I (2) = 82.6 %, p < 0.001) and Tg level (SWD: 0.52, 95 % CI: 0.30-0.73, I (2) = 0 %, p = 0.493) were decreased and no significant publication bias was detectable. CONCLUSIONS: The pooled data indicated that the prognosis improved for patients with localized recurrent thyroid cancers and RFA is a promising treatment for these patients with infeasible surgery.
OBJECTIVES: Our aim was to evaluate the efficacy of ultrasound-guided radiofrequency ablation (RFA) for localized recurrent thyroid cancers. METHODS: We did a systematic review and meta-analysis of the scientific literature by searching the PubMed, Embase, Web of Science,Scopus and the Cochrane Library up to November 26, 2015. We assessed the pooled standard mean difference (SMD) of nodule volume, largest diameter and serum thyroglobulin (Tg) level by comparing pre-RFA with post-RFA using fixed or random-effects model. The Newcastle-Ottawa Scale was used to evaluate the methodological quality of the included studies, risk of bias in the selective populations, comparability of groups and exposure. RESULTS: We finally identified nine articles including 189 patients (male: 54 and female: 135) with 255 tumor lesions, who underwent ultrasound (US)-guided RFA beyond the mean 6 months of follow-up. The results showed that tumor volume (SWD: 0.77, 95 % CI: 0.57-0.97, I (2) = 25.9 %, p = 0.231), largest diameter (SWD: 1.56, 95 % CI: 0.94-2.17, I (2) = 82.6 %, p < 0.001) and Tg level (SWD: 0.52, 95 % CI: 0.30-0.73, I (2) = 0 %, p = 0.493) were decreased and no significant publication bias was detectable. CONCLUSIONS: The pooled data indicated that the prognosis improved for patients with localized recurrent thyroid cancers and RFA is a promising treatment for these patients with infeasible surgery.
Authors: Ji-hoon Kim; Won Sang Yoo; Young Joo Park; Do Joon Park; Tae Jin Yun; Seung Hong Choi; Chul-Ho Sohn; Kyu Eun Lee; Myung-Whun Sung; Yeo-Kyu Youn; Kwang Hyun Kim; Bo Youn Cho Journal: Radiology Date: 2015-04-03 Impact factor: 11.105
Authors: G Mauri; L Cova; T Tondolo; T Ierace; A Baroli; E Di Mauro; C M Pacella; S N Goldberg; L Solbiati Journal: J Clin Endocrinol Metab Date: 2013-05-10 Impact factor: 5.958
Authors: Sun Jin Lee; So Lyung Jung; Bum Soo Kim; Kook Jin Ahn; Hyun Seok Choi; Dong Jun Lim; Min Hee Kim; Ja Seong Bae; Min Sik Kim; Chan Kwon Jung; Se Min Chong Journal: Korean J Radiol Date: 2014-11-07 Impact factor: 3.500
Authors: S Mazzeo; R Cervelli; R Elisei; G Tarantini; C Cappelli; E Molinaro; D Galleri; L De Napoli; C Comite; R Cioni; P Vitti; D Caramella Journal: J Endocrinol Invest Date: 2018-04-23 Impact factor: 4.256
Authors: Giovanni Mauri; Laszlo Hegedüs; Steven Bandula; Roberto Luigi Cazzato; Agnieszka Czarniecka; Oliver Dudeck; Laura Fugazzola; Romana Netea-Maier; Gilles Russ; Göran Wallin; Enrico Papini Journal: Eur Thyroid J Date: 2021-05-25
Authors: Ralph P Tufano; Pia Pace-Asciak; Jonathon O Russell; Carlos Suárez; Gregory W Randolph; Fernando López; Ashok R Shaha; Antti Mäkitie; Juan P Rodrigo; Luiz Paulo Kowalski; Mark Zafereo; Peter Angelos; Alfio Ferlito Journal: Front Endocrinol (Lausanne) Date: 2021-06-24 Impact factor: 5.555